Search
Data
Surveillance systems overview for 2019
This spreadsheet contains all surveillance system overview tables from ECDC's annual epidemiological report for 2019.
- Anthrax
- Botulism
- Campylobacteriosis
- Chikungunya virus disease
- Chlamydia infection
- Cholera
- Crimean-Congo haemorrhagic fever
- Cryptosporidiosis
- Dengue
- Diphtheria
- Ebola haemorrhagic fever
- Echinococcosis
- EU/EEA
- Giardiasis
- Hantavirus infection
- Healthcare-associated infections
- Hepatitis A
- Hepatitis B
- Hepatitis C
- HIV infection
- Influenza
- Invasive Haemophilus influenzae disease
- Lassa fever
- Leptospirosis
- Listeriosis
- Malaria
- Marburg haemorrhagic fever
- Meningococcal disease
- Mumps
- Pertussis
- Plague
- Pneumococcal disease
- Poliomyelitis
- Q fever
- Rabies
- Rift Valley fever
- Salmonellosis
- Severe acute respiratory syndrome (SARS)
- Shigellosis
- Smallpox
- Surveillance
- Verotoxigenic Escherichia coli infection
- West Nile virus infection
Data
Infographic: HIV Infection - late diagnosis
In Europe, every second HIV diagnosis happens at a late stage of infection when the immune system has already started to fail.
Data
Infographic: HIV transmission risk patterns in Europe
This infographic shows the various transmission modes and patterns in Europe
News
ECDC and WHO call for improved HIV testing in Europe
The number of people living with undiagnosed HIV is increasing in the WHO European Region. According to data published today by ECDC and the WHO/Europe, more than 136 000 people were newly diagnosed in 2019 – roughly 20% of these were diagnosed in the EU/EAA and 80% in the eastern part of the European Region. Every second HIV diagnosis (53%) happens at a late stage of the infection, when the immune system has already started to fail. This is a sign that testing strategies in the Region are not working properly to diagnose HIV early.
Publication
HIV/AIDS surveillance in Europe 2020 (2019 data)
This report is the latest in a series published jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe that has been summarizing data on HIV and AIDS in the WHO European Region and in the European Union and European Economic Area (EU/EEA) since 2007.
Event
World AIDS Day 2020: The way towards 2030: diversified testing to diagnose HIV early
One of the targets of the Sustainable Development Goals is to end the AIDS epidemic by 2030. Still, 2 094 AIDS cases were reported in the EU/EEA during 2019. This shows a significant problem with late diagnosis of HIV infection. Detecting HIV only years after the infection is one reason for on-going transmission in Europe. One in every four AIDS cases occurred long after HIV diagnosis, indicating insufficient linkage to HIV care, access to antiretroviral treatment and adherence support.
Publication
HIV Combination prevention: Monitoring implementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia (2018 progress report)
HIV combination prevention is an approach that brings together single prevention initiatives into a comprehensive programme. This approach considers that the offer of multiple evidence-based interventions in a comprehensive programme will have a greater impact on HIV transmission than investing in a single strategy. In this report we
present and test the feasibility of a novel approach to monitoring the implementation of combination HIV prevention at national level.
Event
Spring European Testing Week 2020
European Testing Week is a European campaign that encourages partner organisations, in community, health care and policy institutions, throughout Europe to unite for one week twice a year to increase testing efforts and promote awareness on the benefits of earlier hepatitis and HIV testing.
Publication
Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction
This document summarises evidence from studies included in the licensing file of HPV vaccines together with postlicensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.